Compare Stocks → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BETRFNASDAQ:HSTOOTCMKTS:MRVFFOTCMKTS:NRIFFNASDAQ:PHIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBETRFBetterLife Pharma$0.07$0.07$0.03▼$0.09$8.48M1.3915,169 shs5,010 shsHSTOHistogen$0.35$0.38$0.05▼$1.05$1.49M0.9221,793 shs55,183 shsMRVFFNuvo Pharmaceuticals$0.98$0.98$0.42▼$1.25$11.17M0.9811,250 shsN/ANRIFFNuvo Pharmaceuticals$0.75+0.4%$0.75$0.30▼$0.87$8.52M1.577,337 shs3,000 shsPHIOPhio Pharmaceuticals$0.70-15.6%$0.80$0.50▼$6.85$3.81M1.44423,159 shs649,702 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBETRFBetterLife Pharma0.00%+3.85%+0.08%+30.63%+28.38%HSTOHistogen0.00%-30.00%+7.69%+3.77%-63.16%MRVFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NRIFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHIOPhio Pharmaceuticals-15.56%+7.12%-3.32%+6.93%-79.08%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBETRFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/AMRVFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.8095 of 5 stars3.55.00.00.00.92.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBETRFBetterLife PharmaN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AMRVFFNuvo PharmaceuticalsN/AN/AN/AN/ANRIFFNuvo PharmaceuticalsN/AN/AN/AN/APHIOPhio Pharmaceuticals3.00Buy$4.00470.78% UpsideCurrent Analyst RatingsLatest HSTO, PHIO, MRVFF, NRIFF, and BETRF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/6/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBETRFBetterLife PharmaN/AN/AN/AN/A($0.05) per shareN/AHSTOHistogen$3.77M0.40N/AN/A$3.13 per share0.11MRVFFNuvo Pharmaceuticals$54.98M0.20$0.09 per share11.09($0.80) per share-1.22NRIFFNuvo Pharmaceuticals$52.41M0.16$0.91 per share0.82$1.59 per share0.47PHIOPhio PharmaceuticalsN/AN/AN/AN/A$2.06 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBETRFBetterLife Pharma-$6.90M-$0.02N/A∞N/AN/AN/A-446.36%5/28/2024 (Estimated)HSTOHistogen-$10.62M-$2.81N/A∞N/A-65,142.11%-136.13%-90.87%N/AMRVFFNuvo Pharmaceuticals-$25.70M-$0.12N/A∞N/A20.88%-1,996.22%14.25%N/ANRIFFNuvo Pharmaceuticals$2.53M$0.0418.69∞N/A-2.81%8.02%1.11%N/APHIOPhio Pharmaceuticals-$10.83M-$5.93N/A∞N/AN/A-134.66%-105.86%5/9/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBETRFBetterLife PharmaN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AMRVFFNuvo PharmaceuticalsN/AN/AN/AN/AN/ANRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBETRFBetterLife PharmaN/A0.080.08HSTOHistogenN/A4.054.05MRVFFNuvo Pharmaceuticals9.972.111.77NRIFFNuvo Pharmaceuticals5.272.672.11PHIOPhio PharmaceuticalsN/A5.705.71OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBETRFBetterLife Pharma0.01%HSTOHistogenN/AMRVFFNuvo PharmaceuticalsN/ANRIFFNuvo PharmaceuticalsN/APHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipBETRFBetterLife Pharma34.77%HSTOHistogen3.30%MRVFFNuvo Pharmaceuticals7.00%NRIFFNuvo PharmaceuticalsN/APHIOPhio Pharmaceuticals0.77%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBETRFBetterLife Pharma7113.82 million74.25 millionNot OptionableHSTOHistogen74.27 million4.13 millionNot OptionableMRVFFNuvo Pharmaceuticals10011.40 million10.60 millionNot OptionableNRIFFNuvo Pharmaceuticals9911.40 millionN/ANot OptionablePHIOPhio Pharmaceuticals94.59 million4.56 millionNot OptionableHSTO, PHIO, MRVFF, NRIFF, and BETRF HeadlinesSourceHeadlineWhy Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?benzinga.com - April 22 at 3:21 PMIntratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsfinance.yahoo.com - April 22 at 3:21 PMIntratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsglobenewswire.com - April 22 at 1:10 PMPhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)globenewswire.com - April 16 at 7:30 AMPhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)globenewswire.com - April 11 at 7:30 AMNational Spotlight Features Phio’s Innovative RNAi Technology Platformfinance.yahoo.com - April 3 at 10:33 AMNational Spotlight Features Phio's Innovative RNAi Technology Platformglobenewswire.com - April 3 at 7:30 AMPhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Updateglobenewswire.com - April 2 at 7:30 AMPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignanciesfinance.yahoo.com - March 21 at 7:52 AMPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Researchglobenewswire.com - March 13 at 2:00 PMPhio Pharmaceuticals Corp PHIOmorningstar.com - March 10 at 7:10 AMAnalysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)markets.businessinsider.com - March 6 at 6:26 PMPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disordersfinance.yahoo.com - March 6 at 6:26 PMPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disordersglobenewswire.com - March 6 at 10:30 AMChallenges and Opportunities for Key Players in the Hypopigmentation Disorder Product Marketopprairie.com - February 23 at 1:35 PMDry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030uk.finance.yahoo.com - February 14 at 10:33 AMAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)markets.businessinsider.com - February 6 at 1:30 PMPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignanciesfinance.yahoo.com - January 31 at 8:14 AMPhio Pharmaceuticals: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard; Transfer Of Listingcbonds.com - January 28 at 12:19 PMRecent Insider Activity Could Benefit Phio Pharmaceuticals Corp (PHIO)knoxdaily.com - January 1 at 1:39 PMPhio Pharmaceuticals files to sell 4.42M shares of common stock for holdersmsn.com - December 19 at 9:00 PMWhy Phio Pharmaceuticals Stock Is Nosedivingmsn.com - December 7 at 5:55 PMPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceedsfinance.yahoo.com - December 7 at 12:54 PMPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 10 at 1:31 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBetterLife PharmaOTCMKTS:BETRFBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.HistogenNASDAQ:HSTOHistogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California.Nuvo PharmaceuticalsOTCMKTS:MRVFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.Nuvo PharmaceuticalsOTCMKTS:NRIFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.